CL2015000665A1 - Glucagon analog compound useful for preventing weight gain or promoting weight loss; nucleic acid encoding it; vector; host cell; kit; and production procedure. - Google Patents

Glucagon analog compound useful for preventing weight gain or promoting weight loss; nucleic acid encoding it; vector; host cell; kit; and production procedure.

Info

Publication number
CL2015000665A1
CL2015000665A1 CL2015000665A CL2015000665A CL2015000665A1 CL 2015000665 A1 CL2015000665 A1 CL 2015000665A1 CL 2015000665 A CL2015000665 A CL 2015000665A CL 2015000665 A CL2015000665 A CL 2015000665A CL 2015000665 A1 CL2015000665 A1 CL 2015000665A1
Authority
CL
Chile
Prior art keywords
kit
vector
nucleic acid
host cell
acid encoding
Prior art date
Application number
CL2015000665A
Other languages
Spanish (es)
Inventor
Wolfgang Rist
Ditte Riber
Keld Fosgerau
Leo Thomas
Jakob Lind Tolborg
Rasmus Just
Dieter Wolfgang Hamprecht
Robert Augustin
Pia Norregard
Original Assignee
Boehringer Ingelheim Int
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Zealand Pharma As filed Critical Boehringer Ingelheim Int
Publication of CL2015000665A1 publication Critical patent/CL2015000665A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015000665A 2012-09-17 2015-03-17 Glucagon analog compound useful for preventing weight gain or promoting weight loss; nucleic acid encoding it; vector; host cell; kit; and production procedure. CL2015000665A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701952P 2012-09-17 2012-09-17
EP12184744 2012-09-17
US201361784294P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2015000665A1 true CL2015000665A1 (en) 2015-06-26

Family

ID=46851874

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000665A CL2015000665A1 (en) 2012-09-17 2015-03-17 Glucagon analog compound useful for preventing weight gain or promoting weight loss; nucleic acid encoding it; vector; host cell; kit; and production procedure.

Country Status (25)

Country Link
US (3) US9180169B2 (en)
EP (1) EP2895505B1 (en)
JP (1) JP6334537B2 (en)
KR (1) KR101667948B1 (en)
CN (1) CN104812772B (en)
AP (1) AP2015008320A0 (en)
AR (1) AR092589A1 (en)
AU (1) AU2013314182B2 (en)
BR (1) BR112015005783B1 (en)
CA (1) CA2884803C (en)
CL (1) CL2015000665A1 (en)
CO (1) CO7400885A2 (en)
EA (1) EA030001B1 (en)
HK (1) HK1206757A1 (en)
IL (1) IL237518A (en)
MA (1) MA37983A1 (en)
MX (1) MX359690B (en)
PE (1) PE20151178A1 (en)
PH (1) PH12015500531A1 (en)
PL (1) PL2895505T3 (en)
SG (1) SG11201502021SA (en)
TN (1) TN2015000071A1 (en)
TW (1) TWI608013B (en)
UY (1) UY35030A (en)
WO (1) WO2014041195A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
UA104766C2 (en) 2009-07-13 2014-03-11 Зіленд Фарма А/С Acylated glucagon analogues
WO2011088837A1 (en) * 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
CN103068841A (en) 2010-06-24 2013-04-24 西兰制药公司 Glucagon analogues
CN104144704B (en) 2011-11-03 2018-03-23 西兰制药公司 The receptor agonist peptides gastrin conjugates of GLP 1
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
MX356957B (en) 2012-07-23 2018-06-20 Zealand Pharma As Glucagon analogues.
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
RU2652783C2 (en) 2012-12-21 2018-05-03 Санофи Dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG11201507382QA (en) 2013-03-14 2015-10-29 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
CN105849122B (en) 2013-11-06 2021-04-30 西兰制药公司 GIP-GLP-1 dual agonist compounds and methods
TR201902516T4 (en) 2013-11-06 2019-03-21 Zealand Pharma As Glucagon-glp-1-envy triple agonist compounds.
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3511331A1 (en) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
MD3258919T3 (en) 2015-02-17 2023-04-30 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
SG11201707286UA (en) 2015-03-18 2017-10-30 Zealand Pharma As Amylin analogues
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN107636010B (en) * 2015-04-16 2021-10-01 西兰制药公司 Acylated glucagon analogues
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
AR104932A1 (en) 2015-06-22 2017-08-23 Lilly Co Eli GLUCAGON AND PEPTIDE-1 CO-AGONIST COMPOUNDS SIMILAR TO GLUGACON (GLP-1)
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
CN105254720B (en) * 2015-11-18 2018-10-09 暨南大学 A kind of polyceptor agonist PO13 and application
GB2566228A (en) 2016-06-09 2019-03-06 AmideBio LLC Glucagon analogs and methods of use thereof
MX2019001427A (en) 2016-08-05 2019-06-10 Boehringer Ingelheim Int Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
CN117384274A (en) 2016-12-09 2024-01-12 西兰制药公司 Acylated GLP-1/GLP-2 dual agonists
WO2019149657A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
US11136337B2 (en) 2018-02-02 2021-10-05 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
JOP20200191A1 (en) 2018-02-02 2020-07-29 Boehringer Ingelheim Int Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020007994A (en) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors.
TWI771669B (en) 2019-04-26 2022-07-21 美商美國禮來大藥廠 Method for preparing stable peptide formulations
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
CN115916789A (en) 2020-05-22 2023-04-04 勃林格殷格翰国际有限公司 Continuous process for preparing alkyl 7-amino-5-methyl- [1,2,5] oxadiazolo [3,4-b ] pyridinecarboxylic acid esters
DK4153599T3 (en) 2020-05-22 2024-06-17 Boehringer Ingelheim Int PROCEDURE FOR PREPARING ALKYL 7-AMINO-5-METHYL-[1,2,5]OXADIAZOLO[3,4-B]PYRIDINE CARBOXYLATE
KR20230045088A (en) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 Soluble NPY2 receptor agonists
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288627A (en) 1980-02-12 1981-09-08 Phillips Petroleum Company Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
WO1991017243A1 (en) 1990-05-09 1991-11-14 Novo Nordisk A/S A cellulase preparation comprising an endoglucanase enzyme
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5523449A (en) 1995-05-17 1996-06-04 Bayer Corporation Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
DE59712555D1 (en) 1996-06-05 2006-04-06 Roche Diagnostics Gmbh EXENDIN ANALOGUE, PROCESS FOR THE PRODUCTION THEREOF AND THE MEDICAMENTS CONTAINING THEREOF
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
ATE493998T1 (en) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION CONTAINING AN EXENDIN-4 PEPTIDE
JP3149958B2 (en) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
CA2265900C (en) 1996-09-09 2007-07-31 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
IL128828A0 (en) 1996-09-09 2000-01-31 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxy acid linker
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
AU5065198A (en) 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
AU739020B2 (en) 1997-01-07 2001-10-04 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
WO1998035033A1 (en) 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
TR199903120T2 (en) 1997-05-07 2000-05-22 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften New cysteine derivatives, processes for their production, and pharmaceuticals containing them.
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
BR9815670A (en) 1997-11-14 2000-10-17 Amylin Pharmaceuticals Inc Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
DE69839021T3 (en) 1997-11-14 2013-08-08 Amylin Pharmaceuticals, Llc NOVEL EXENDIN AGONISTS
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO1999049788A1 (en) 1998-03-30 1999-10-07 Focus Surgery, Inc. Ablation system
SE9802080D0 (en) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
EP2028269B1 (en) 1998-08-10 2015-10-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4 and uses thereof
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CZ295891B6 (en) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application GLP-1 analogues substituted in position 35, their use and pharmaceutical compositions in which the analogues are comprised
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
DE60032331T2 (en) 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego EXENDINE FOR GLUCAGON SUPPRESSION
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
CN1344248A (en) 1999-03-17 2002-04-10 诺沃挪第克公司 Method for acylating peptides and novel acylating agents
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
BR0010705A (en) 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EA003922B1 (en) 1999-05-17 2003-10-30 Конджачем, Инк. Long lasting insulinotropic peptides
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP4480329B2 (en) 2000-10-20 2010-06-16 アミリン・ファーマシューティカルズ，インコーポレイテッド Treatment of hibernating myocardium and diabetic cardiomyopathy with GLP-1 peptide
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US20050014679A1 (en) 2001-12-20 2005-01-20 Beals John Michael Insulin molecule having protracted time action
ES2327328T3 (en) 2002-07-04 2009-10-28 Zealand Pharma A/S GLP-1 AND PROCEDURES FOR THE TREATMENT OF DIABETES.
AU2003268621B2 (en) 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2518776A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
US7623530B2 (en) 2003-11-20 2009-11-24 Nokia Corporation Indication of service flow termination by network control to policy decision function
CA2554458A1 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005303777B2 (en) 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
ES2385093T3 (en) 2005-06-13 2012-07-18 Imperial Innovations Limited Oxintomodulin analogues and their effects on eating behavior
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
ITMI20061607A1 (en) 2006-08-09 2008-02-10 Maria Vincenza Carriero PEPTIDES WITH PHARMACOLOGICAL ACTIVITY
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2008071010A1 (en) 2006-12-12 2008-06-19 Waratah Pharmaceuticals Inc. Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CN101790538B (en) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 Ucagon/glp-1 receptor co-agonists
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
FR2917552B1 (en) 2007-06-15 2009-08-28 Sagem Defense Securite METHOD FOR REGULATING THE TRANSMISSION GEIGE WITHIN A RECEPTION TERMINAL
DK2158214T3 (en) 2007-06-15 2011-12-05 Zealand Pharma As Glucagon analogues
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
GB2455553B (en) 2007-12-14 2012-10-24 Nuaire Ltd Motor mounting assembly for an axial fan
AU2009203810B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
RU2524423C2 (en) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Novel insulin derivatives with extremely delayed time/action profile
DE102008003568A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
DE102008003566A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
BRPI0911571A2 (en) 2008-04-22 2018-04-03 Univ Case Western Reserve method for treating a mammal, insulin analog, nucleic acid and host cell
TWI451876B (en) 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
PE20100056A1 (en) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS AS GIP AGONISTS
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
CN104447980A (en) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL219335B1 (en) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków New slow-release insulin analogues
ES2552636T3 (en) 2008-07-31 2015-12-01 Case Western Reserve University Halogen stabilized insulin
EA020019B1 (en) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Analogues of glucose-dependent insulinotropic polypeptide
CN102149411A (en) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 Method of acylating a peptide or protein
CA2747197A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
MA32970B1 (en) 2008-12-15 2012-01-02 Zealand Pharma As Isotope glucagon
EP2370460B1 (en) 2008-12-15 2014-04-30 Zealand Pharma A/S Glucagon analogues
CN102282166B (en) 2008-12-15 2015-04-01 西兰制药公司 Glucagon analogues
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
CN102245624B (en) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 Insulin prodrug based on amide
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
CN101519446A (en) 2009-03-31 2009-09-02 上海一就生物医药有限公司 Method for preparing recombinant human insulin and analogs of recombinant human insulin
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
UA104766C2 (en) 2009-07-13 2014-03-11 Зіленд Фарма А/С Acylated glucagon analogues
CN101729930B (en) * 2009-11-17 2012-07-04 中兴通讯股份有限公司 Method for realizing multi-intelligent service fusion via intelligent network gateway
CN102791731B (en) 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 GLP-1 sum analogous to general Dedekind sum
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
WO2011088837A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
JP2013523620A (en) 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス New glucagon analog
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
BR112012027545B1 (en) 2010-04-27 2020-09-24 Betta Pharmaceuticals Co., Ltd. COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
UY33462A (en) * 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
CN103068841A (en) 2010-06-24 2013-04-24 西兰制药公司 Glucagon analogues
JP6039569B2 (en) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス Double acylated GLP-1 derivative
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
WO2012140117A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012150503A2 (en) * 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en) * 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2718317B1 (en) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
IN2014CN02448A (en) 2011-09-23 2015-06-19 Novo Nordisk As
KR20140114845A (en) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 Glucagon analogues
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
MX356957B (en) 2012-07-23 2018-06-20 Zealand Pharma As Glucagon analogues.
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105849122B (en) 2013-11-06 2021-04-30 西兰制药公司 GIP-GLP-1 dual agonist compounds and methods
US9963496B2 (en) 2014-02-18 2018-05-08 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
CN107636010B (en) 2015-04-16 2021-10-01 西兰制药公司 Acylated glucagon analogues

Also Published As

Publication number Publication date
TWI608013B (en) 2017-12-11
US10253081B2 (en) 2019-04-09
US20190055296A1 (en) 2019-02-21
JP2015533803A (en) 2015-11-26
MX359690B (en) 2018-10-05
SG11201502021SA (en) 2015-05-28
WO2014041195A1 (en) 2014-03-20
EP2895505B1 (en) 2019-11-06
PE20151178A1 (en) 2015-08-16
CA2884803A1 (en) 2014-03-20
EP2895505A1 (en) 2015-07-22
WO2014041195A8 (en) 2015-02-26
US9180169B2 (en) 2015-11-10
PH12015500531A1 (en) 2015-05-11
TW201412769A (en) 2014-04-01
KR20150056847A (en) 2015-05-27
AU2013314182A1 (en) 2015-04-02
CN104812772B (en) 2018-12-07
TN2015000071A1 (en) 2016-06-29
US20140080757A1 (en) 2014-03-20
MA37983A1 (en) 2016-07-29
US20160009777A1 (en) 2016-01-14
PL2895505T3 (en) 2020-05-18
CA2884803C (en) 2018-01-16
UY35030A (en) 2014-03-31
AR092589A1 (en) 2015-04-29
US9975939B2 (en) 2018-05-22
BR112015005783B1 (en) 2021-11-03
KR101667948B1 (en) 2016-10-20
BR112015005783A8 (en) 2018-01-30
JP6334537B2 (en) 2018-05-30
AP2015008320A0 (en) 2015-03-31
CN104812772A (en) 2015-07-29
IL237518A0 (en) 2015-04-30
IL237518A (en) 2017-01-31
EA030001B1 (en) 2018-06-29
CO7400885A2 (en) 2015-09-30
AU2013314182B2 (en) 2018-02-22
HK1206757A1 (en) 2016-01-15
BR112015005783A2 (en) 2017-07-04
EA201590294A1 (en) 2015-09-30
MX2015003293A (en) 2016-01-22

Similar Documents

Publication Publication Date Title
CL2015000665A1 (en) Glucagon analog compound useful for preventing weight gain or promoting weight loss; nucleic acid encoding it; vector; host cell; kit; and production procedure.
AR113177A2 (en) POLYPEPTIDES THAT HAVE LYSOZYME ACTIVITY AND POLYNUCLEOTIDES THAT CODE THEM
SG11201605344YA (en) Analysis of nucleic acids associated with single cells using nucleic acid barcodes
BR112014025695A2 (en) NUCLEIC ACID SAMPLE PREPARATION
IL241426B (en) Nucleic acid amplification
IL241269A0 (en) Nucleic acid amplification
EP2844261A4 (en) SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2917372A4 (en) Nucleic acid sequencing using tags
DK3623481T3 (en) COMPOSITIONS FOR NUCLEIC ACID SEQUENCE
SG11201406717RA (en) Nucleic acid amplification
EP3022323A4 (en) Specific nucleic acid amplification with compounded selectivity
BR112014024421A2 (en) Sample Preparation Methods for Nucleic Acid Amplification
GB201219137D0 (en) Direct nucleic acid amplification kit, reagent and method
EP3134550A4 (en) High-throughput structure determination using nucleic acid calipers
DE112013002360T8 (en) The reagent
DK2890814T3 (en) MULTIPLE PHASE NUCLEIC ACID AMPLIFICATION
BR112013010169A8 (en) use of monascus in the production of organic acid.
EP2915815A4 (en) New modified nucleic acid
DK2586658T4 (en) Vehicle construction for the transport of freight, which can be loosely loaded or stacked
HK1232259A1 (en) Nucleic acid amplification
IL241273A0 (en) Nucleic acid amplification
PL2861618T3 (en) Bag3 as biochemical serum and tissue marker
DK3330374T3 (en) GLYCOSYLTRANSFERASE GLYCOSYLING FLAVOKER ACID AND / OR KERM ACID
SG11201507104WA (en) Novel nucleic acid molecules
BR112014032072A2 (en) nucleic acid detection method and nucleic acid detection kit.